Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HALO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHalozyme elects James Daly to board, term through 2029 annual meeting
Filed September 30, 2026 · Period ending September 28, 2026 · ~1 min read
Key Changes
-
low
James Daly was elected to the Board of Directors effective September 28, 2026, in the class with terms ending at the 2029 annual meeting.
Item 5.02 verify on EDGAR → -
low
Daly was not initially assigned to any Board committee and will receive standard non-employee director compensation.
Item 5.02 verify on EDGAR → -
low
The filing states there are no arrangements or related person transactions between Daly and the company.
Item 5.02 verify on EDGAR →
Summary
Halozyme Therapeutics added James Daly to its Board of Directors on September 28, 2026. He will serve in the class of directors whose terms run until the 2029 annual meeting and has not yet been assigned to any board committee. Daly will be compensated under the company's standard non-employee director program, which includes cash retainers and equity awards.
The filing confirms that Daly's election was not the result of any special arrangement and that there are no related person transactions between him and the company. This is a routine governance matter with no immediate red flags.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee.
The company added a new independent director, James Daly, to its board. He will serve in the class of directors whose terms run until the 2029 annual meeting and has not yet been assigned to any board committee.
Added in current filing · verify on EDGAR →
Mr. Daly will receive compensation for his services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time.
Daly will be compensated under the standard non-employee director program, which includes cash retainers and equity awards. The filing notes the program details were described in the 2026 proxy statement.
Added in current filing · verify on EDGAR →
There are no arrangements or understandings pursuant to which Mr. Daly was elected as a director and there are no related person transactions between the Company and Mr. Daly.
The filing confirms Daly's election was not the result of any special arrangement and that he has no related person transactions with the company, indicating a standard independent director appointment.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 1, 2026 · How we verify